EMU - Cross-sectional Study on Migraine Patients in Emergency Service Departments: Diagnosis and Treatment

Head :Grun-Overdyking Aurélie, Pfizer

Last update : 01/01/2018 | Version : 1 | ID : 117

General	
Identification	
Detailed name	Cross-sectional Study on Migraine Patients in Emergency Service Departments: Diagnosis and Treatment
Sign or acronym	EMU
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL no. 906286
General Aspects	
Medical area	Emergency medicine Neurology
Keywords	emergency services
Scientific investigator(s) (Contact)	
Name of the director	Grun-Overdyking
Surname	Aurélie
Address	23-25, avenue du dr Lannelongue, 75668 Paris cedex 14
Phone	+33 (0)1 58 07 33 02
Email	aurelie.grun-overdyking@pfizer.com
Unit	Pfizer
Collaborations	
Funding	
Funding status	Private

Details	Pfizer
Governance of the database	
Sponsor(s) or organisation(s) responsible	Pfizer
Organisation status	Private
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding	Recruitment by participating doctors
sample selection.	
Database objective	
	 Primary: To estimate the frequency of patients admitted with headaches and to estimate the frequency of patients diagnosed with migraine. To characterise patients diagnosed with migraines attending emergency services based on demographic data and migraine history (age, severity). To describe the treatment of patients diagnosed with a migraine during emergency service consultation. Secondary: To describe the treatment of patients diagnosed with a migraine according to the type of migraine. To describe the frequency of patients diagnosed with a migraine and their treatment by emergency structure type. To describe treatment follow-up.

- questions. Patients agreeing to participate in the survey. Patients admitted to emergency department

Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	Metropolitan France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2006
Date of last collection (YYYY or MM/YYYY)	2008
Size of the database	
Size of the database (number of individuals)	< 500 individuals
Details of the number of individuals	479
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Declarative data
Clinical data (detail)	Direct physical measures Medical registration
Declarative data (detail)	Face to face interview
Presence of a biobank	No

Health parameters studied	Health event/morbidity
Procedures	
Data collection method	Paper CRF
Participant monitoring	Yes
Details on monitoring of participants	6-8 weeks
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Terms of data access (charter for data provision, format of data, availability delay)	Submission of project to the Pfizer scientific team.
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only